Scientific Background and Reference Sources
AAFP. Autoimmune Rheumatic Diseases. Updated April 2019. https://www.aafp.org/dam/AAFP/images/about-us/content/Quest_SH8265_SoH_Autoimmune%20Rheumatic%20Diseases_HealthcareProviders_April_FINAL-2.pdf
Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. Nat Med. Jul 2022;28(7):1363-1371. doi:10.1038/s41591-022-01880-6
Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Advances in immunology. 1989;44:93-151.
Satoh M, Chan EK, Sobel ES, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert review of clinical immunology. Sep 2014;3(5):721-38. doi:10.1586/1744666x.3.5.721
Tebo AE. Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies. Clinical and vaccine immunology : CVI. Dec 2017;24(12)doi:10.1128/cvi.00270-17
Bloch D. Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP. Updated May 7, 2024. https://www.uptodate.com/contents/antibodies-to-double-stranded-ds-dna-sm-and-u1-rnp
Global Autoimmune Institute. The Global Landscape of Autoimmune Disease. Updated February 20, 2024. https://www.autoimmuneinstitute.org/articles/the-global-landscape-of-autoimmune-disease/
Simon TA, Kawabata H, Ray N, Baheti A, Suissa S, Esdaile JM. Prevalence of Co-existing Autoimmune Disease in Rheumatoid Arthritis: A Cross-Sectional Study. Advances in therapy. Nov 2017;34(11):2481-2490. doi:10.1007/s12325-017-0627-3
CDC. People with Lupus. Updated May 15, 2024. https://www.cdc.gov/lupus/data-research/index.html
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). Nov 1 2017;56(11):1945-1961. doi:10.1093/rheumatology/kex260
Zucchi D, Elefante E, Calabresi E, Signorini V, Bortoluzzi A, Tani C. One year in review 2019: systemic lupus erythematosus. Clin Exp Rheumatol. Sep-Oct 2019;37(5):715-722.
Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. Jun 8 2019;393(10188):2332-2343. doi:10.1016/s0140-6736(19)30237-5
Finzel S, Schaffer S, Rizzi M, Voll RE. [Pathogenesis of systemic lupus erythematosus]. Z Rheumatol. Nov 2018;77(9):789-798. Pathogenese des systemischen Lupus erythematodes. doi:10.1007/s00393-018-0541-3
Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. Jan 2019;96:1-13. doi:10.1016/j.jaut.2018.11.001
Thong B, Olsen NJ. Systemic lupus erythematosus diagnosis and management. Rheumatology (Oxford). Apr 1 2017;56(suppl_1):i3-i13. doi:10.1093/rheumatology/kew401
Bhana S. Antinuclear Antibodies (ANA). Updated February 2023. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Antinuclear-Antibodies-ANA
Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol. Nov 2019;38(11):2967-2976. doi:10.1007/s10067-019-04684-1
Luan H, Gu W, Li H, et al. Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients. J Transl Med. Dec 7 2021;19(1):500. doi:10.1186/s12967-021-03169-7
Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. Jan 2021;80(1):96-102. doi:10.1136/annrheumdis-2020-217209
Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. Jun 2020;110:102400. doi:10.1016/j.jaut.2019.102400
Cohen S, Wells AF, Curtis JR, et al. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study. Rheumatol Ther. Sep 2021;8(3):1159-1176. doi:10.1007/s40744-021-00330-y
Baker JF. Diagnosis and differential diagnosis of rheumatoid arthritis. Updated March 21, 2024. https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-rheumatoid-arthritis
Taylor P, Maini R. Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis. Updated April 22, 2024. https://www.uptodate.com/contents/investigational-biologic-markers-in-the-diagnosis-and-assessment-of-rheumatoid-arthritis
McArdle A, Flatley B, Pennington SR, FitzGerald O. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther. Jun 1 2015;17(1):141. doi:10.1186/s13075-015-0652-z
Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). Dec 2012;64(12):1794-803. doi:10.1002/acr.21767
Centola M, Cavet G, Shen Y, et al. Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLoS One. 2013;8(4)doi:10.1371/journal.pone.0060635
Shmerling R. Rheumatoid factor: Biology and utility of measurement. Updated January 27, 2025. https://www.uptodate.com/contents/rheumatoid-factor-biology-and-utility-of-measurement
Shapiro SC. Biomarkers in Rheumatoid Arthritis. Cureus. May 16 2021;13(5):e15063. doi:10.7759/cureus.15063
Castro CTd, Queiroz MJd, Albuquerque FC, et al. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis. Systematic Review. Frontiers in Pharmacology. 2022-August-11 2022;13doi:10.3389/fphar.2022.927179
Bergman MJ, Kivitz AJ, Pappas DA, et al. Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. Rheumatol Ther. Dec 2020;7(4):775-792. doi:10.1007/s40744-020-00226-3
Curtis JR, Schabert VF, Harrison DJ, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. Jul 1 2014;36(7):996-1004. doi:10.1016/j.clinthera.2014.05.062
Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi:10.1172/jci78084
Aggarwal A. Role of autoantibody testing. Best practice & research Clinical rheumatology. Dec 2014;28(6):907-20. doi:10.1016/j.berh.2015.04.010
Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmunity reviews. Jun 2015;14(6):555-63. doi:10.1016/j.autrev.2015.01.017
Selmi C, Ceribelli A, Generali E, et al. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmunity reviews. Feb 2016;15(2):162-6. doi:10.1016/j.autrev.2015.10.007
Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; the tart cell and the L.E. cell. Proceedings of the staff meetings Mayo Clinic. Jan 21 1948;23(2):25-8.
ACR. Position Statement on Methodology of Testing for Antinuclear Antibodies. American College Of Rheumatology; 2015. https://primexlab.com/wp-content/uploads/2016/10/Methodology-of-Testing-Antinuclear-Antibodies-Position-Statement.pdf
Chan EK, Damoiseaux J, de Melo Cruvinel W, et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus. Jul 2016;25(8):797-804. doi:10.1177/0961203316640920
Bloch D. Measurement and clinical significance of antinuclear antibodies. Updated April 4, 2024. https://www.uptodate.com/contents/measurement-and-clinical-significance-of-antinuclear-antibodies
Yoo IY, Oh JW, Cha HS, Koh EM, Kang ES. Performance of an Automated Fluorescence Antinuclear Antibody Image Analyzer. Annals of laboratory medicine. May 2017;37(3):240-247. doi:10.3343/alm.2017.37.3.240
Wallace DJ, Gladman D. Systemic lupus erythematosus in adults: Clinical manifestations and diagnosis. Updated February 12, 2025. https://www.uptodate.com/contents/systemic-lupus-erythematosus-in-adults-clinical-manifestations-and-diagnosis
Tonutti E, Bizzaro N, Morozzi G, et al. The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics. Auto Immun Highlights. 2016;7(1)doi:10.1007/s13317-016-0080-3
AVISE. AVISE Testing Exclusively from Exagen Inc. https://avisetest.com/provider/
Exagen. AVISE Lupus. https://exagen.com/tests/lupus/
van der Helm-van Mil AHM, Knevel R, Cavet G, Huizinga TWJ, Haney DJ. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford). 2013:839-46. vol. 5.
Progenotes Diagnostics Inc. aiSLE DX. https://www.progentec.com/aisle-dx
KSL Diagnostics-Beutner. Seronegative Rheumatoid Arthritis Profile. https://www.beutnerlabs.com/rheumatoid-arthritis-ra-laboratory-testing
Immco Diagnostics. Early Sjögren’s Syndrome Profile. 2017;
van der Pol P, Bakker-Jonges LE, Kuijpers J, Schreurs MWJ. Analytical and clinical comparison of two fully automated immunoassay systems for the detection of autoantibodies to extractable nuclear antigens. Clinica chimica acta; international journal of clinical chemistry. Jan 2018;476:154-159. doi:10.1016/j.cca.2017.11.014
Tipu HN, Bashir MM. Determination of Specificity and Pattern of Antinuclear Antibodies (ANA) in Systemic Rheumatic Disease Patients Positive for ANA Testing. J Coll Physicians Surg Pak. Jan 2018;28(1):40-43.
Kim J, Lee W, Kim GT, et al. Diagnostic utility of automated indirect immunofluorescence compared to manual indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. Seminars in arthritis and rheumatism. Feb 2019;48(4):728-735. doi:10.1016/j.semarthrit.2018.03.015
Dervieux T, Conklin J, Ligayon JA, et al. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. J Immunol Methods. Jul 2017;446:54-59. doi:10.1016/j.jim.2017.04.001
Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med. 2014;1(1):e000056. doi:10.1136/lupus-2014-000056
Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. Jan 2020;72(1):78-88. doi:10.1002/art.41093
Oglesby A, Korves C, Laliberté F, et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy. Apr 2014;12(2):179-90. doi:10.1007/s40258-014-0085-x
Yeo AL, Le S, Ong J, et al. Utility of repeated antinuclear antibody tests: a retrospective database study. The Lancet Rheumatology. 2020/07/01/ 2020;2(7):e412-e417. doi:10.1016/S2665-9913(20)30084-9
Deng X, Peters B, Ettore MW, et al. Utility of Antinuclear Antibody Screening by Various Methods in a Clinical Laboratory Patient Cohort. J Appl Lab Med. Jul 1 2016;1(1):36-46. doi:10.1373/jalm.2016.020172
Alsaed OS, Alamlih LI, Al-Radideh O, Chandra P, Alemadi S, Al-Allaf AW. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases. Sci Rep. Apr 15 2021;11(1):8229. doi:10.1038/s41598-021-87366-w
Wallace DJ, Alexander RV, O'Malley T, et al. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus science & medicine. 2019;6(1):e000349. doi:10.1136/lupus-2019-000349
Mossell J, Goldman JA, Barken D, Alexander RV. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Open Rheumatol J. 2016;10:71-80. doi:10.2174/1874312901610010071
Liang E, Taylor M, McMahon M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. Lupus Science & Medicine. 2020;7(1):e000345. doi:10.1136/lupus-2019-000345
Alexander RV, Rey DS, Conklin J, et al. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. Lupus Sci Med. Jul 2021;8(1)doi:10.1136/lupus-2021-000528
Clarke AE, Weinstein A, Piscitello A, et al. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP). ACR Open Rheumatology. 2020;n/a(n/a)doi:10.1002/acr2.11177
Mellors T, Withers JB, Ameli A, et al. Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. Network and Systems Medicine. July 14, 2020 2020;3(1):91-104. doi:10.1089/nsm.2020.0007
Hirata S, Dirven L, Shen Y, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford). Jul 2013;52(7):1202-7. doi:10.1093/rheumatology/kes362
Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. Oct 2012;71(10):1692-7. doi:10.1136/annrheumdis-2011-200963
Li W, Sasso EH, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Current medical research and opinion. Jan 2013;29(1):85-92. doi:10.1185/03007995.2012.753042
Li W, Sasso EH, van der Helm-van Mil AH, Huizinga TW. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology (Oxford). Feb 2016;55(2):357-66. doi:10.1093/rheumatology/kev341
Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL. Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Seminars in arthritis and rheumatism. Feb 2018;47(4):472-477. doi:10.1016/j.semarthrit.2017.07.010
Curtis JR, Flake DD, Weinblatt ME, et al. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology (Oxford). May 1 2019;58(5):874-883. doi:10.1093/rheumatology/key367
Brahe CH, Ostergaard M, Johansen JS, et al. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scand J Rheumatol. Jan 2019;48(1):9-16. doi:10.1080/03009742.2018.1464206
Ma MHY, Defranoux N, Li W, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Research & Therapy. 2020/06/24 2020;22(1):158. doi:10.1186/s13075-020-02240-w
Curtis JR, Weinblatt ME, Shadick NA, et al. Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. Arthritis Research & Therapy. 2021/01/04 2021;23(1):1. doi:10.1186/s13075-020-02389-4
Fleischmann R, Liu J, Zhu J, Segurado OG, Furst DE. Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. Arthritis Care Res (Hoboken). Sep 2022;74(9):1477-1483. doi:10.1002/acr.24583
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. Sep 1997;40(9):1725. doi:10.1002/art.1780400928
CDC. Lupus Basics. Updated May 15, 2024. https://www.cdc.gov/lupus/about/index.html
Mosca M, Costenbader KH, Johnson SR, et al. Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis Rheumatol. Jan 2019;71(1):91-98. doi:10.1002/art.40674
ACR. 1997 Update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf
ACR. Policy & Position Statements. https://rheumatology.org/policy-position-statements
Yazdany J, Schmajuk G, Robbins M, et al. Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question. Arthritis Care & Research. 2013;65(3):329-339. doi:10.1002/acr.21930
Rouster-Stevens KA, Ardoin SP, Cooper AM, et al. Choosing Wisely: the American College of Rheumatology's Top 5 for pediatric rheumatology. Arthritis Care Res (Hoboken). May 2014;66(5):649-57. doi:10.1002/acr.22238
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). Jul 2021;73(7):924-939. doi:10.1002/acr.24596
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. Sep 2019;78(9):1151-1159. doi:10.1136/annrheumdis-2018-214819
Josef SS, Robert BML, Sytske Anne B, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2023;82(1):3. doi:10.1136/ard-2022-223356
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. Aug 2012;64(8):2677-86. doi:10.1002/art.34473
British Columbia Rheumatoid Arthritis. Diagnosis, Management and Monitoring Guideline. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/rheumatoid-arthritis
Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Management of rheumatoid arthritis: summary of NICE guidance. Bmj. Mar 16 2009;338:b702. doi:10.1136/bmj.b702
RACGP. Recommendations for the diagnosis and management of early rheumatoid arthritis. https://www.racgp.org.au/FSDEDEV/media/documents/Clinical%20Resources/Guidelines/Joint%20replacement/Rheumatoid-arthritis-recommendations.pdf
Medical Director Review 2/2021
Medical Director Review 4/2021
Medical Director Review 4/2022
Medical Director Review 4/2023
Medical Director Review 4/2024
Medical Director Review 4/2025